For instance, a clinical mTOR inhibitor, blocking mTOR-dependent 4E-BP1 phosphorylation in human lymphomas, confers such synthetic lethality with MYC, demonstrating that MYC can become better druggable by applying this principle (33, 92). The gene discussed is MTOR; the disease is lymphoma.